Common readers know that we don’t get distracted or unnerved by dropping inventory costs. It’s pure to really feel a bit panicky. You understand how a lot of our article titles on gene-sequencing shares final 12 months had been variations on: “XXX Inventory Plummets: Why We’re Not Leaping to Our Loss of life?” About 15% of our Nanalyze Disruptive Tech Portfolio is weighted in life sciences – and practically all of that’s linked to gene-sequencing shares. Should you’re in it for the lengthy haul, you don’t bail except you’ve misplaced religion in your funding thesis. We nonetheless imagine genomics and gene-sequencing applied sciences might be key drivers in areas like precision medication and longevity, particularly in monitoring and treating ailments resembling most cancers.
The market chief in next-generation sequencing, Illumina (ILMN), has seemed like something however that with its failed GRAIL acquisition final 12 months. A few rivals enjoying the lengthy recreation with long-read sequencing (LRS) look like gaining traction. Whereas we like Pacific Bioscie…
